TCR-T cell therapy specialist Affini-T Therapeutics Inc. (Seattle, Boston) has raised $175m Series A fnancing co-Led by Vida Ventures and Leaps by Bayer
Bavarian Nordic is to receive up to US$225 and double-digit royalties for granting exclusive Chinese commercialisation rights for MVA-BN® RSV to Nuance Pharma.
Switzerland is keeping its moratorium on GMO cultivation until 2025, but paving the way for exceptions in precision breeding.
Gilde Healthcare Private Equity IV (GHPE IV) has closed at €517m for investments in proifitable healthcare companies in the lower mid-market in North-west Europe.
With €80m from a Series B financing in its pocket, Belgian Precirix NV plans to advance its pipeline of precision radiopharmaceuticals.
Sanofi has secured money from Blackstone Life Sciences to speed up development of its daratumumab competitor isatuximab in multiple myeloma.
US Life Science leaders pledge to economically disengage from Russia.
Scenic Biotech BV will use an incoming $31m (€28) Series A financing to advance its pipeline of genetic modifiers, a new molecular entity in cancer and rare disease.
·
French venture capital expert Kurma Partners has closed its Growth Opportunities Fund at €160m and targets a final closing at €250m.
Moderna will build its first mRNA production facility in Kenya, investing up to US$500m.